Deutsche Bank AG Has $4.87 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Deutsche Bank AG boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 258,964 shares of the biotechnology company's stock after acquiring an additional 37,686 shares during the quarter. Deutsche Bank AG owned 0.21% of Arrowhead Pharmaceuticals worth $4,869,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at about $38,000. Van ECK Associates Corp increased its stake in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,250 shares during the period. KBC Group NV increased its stake in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at about $205,000. Institutional investors own 62.61% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on ARWR shares. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. B. Riley reaffirmed a "buy" rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Finally, Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.13.

Insider Activity at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the transaction, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at $61,220,021.39. This trade represents a 1.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 275,880 shares of company stock worth $4,034,037 over the last ninety days. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR traded down $0.26 during mid-day trading on Friday, hitting $15.13. 1,230,383 shares of the company traded hands, compared to its average volume of 1,505,636. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The business has a 50-day moving average of $13.32 and a 200 day moving average of $17.63. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -2.93 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period last year, the company earned ($1.02) earnings per share. As a group, equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.